Varex Imaging (VREX) Q2 2026: Industrial Segment Grows High Single Digits, Offsetting EMEA Weakness
Varex Imaging’s Q2 2026 results highlight a stable demand environment and ongoing investment in growth initiatives, even as EMEA revenue and the medical segment remain subdued. Industrial growth and a diversified pipeline in security inspection are key offsets, but management’s tone reflects a more cautious stance on macro and cost headwinds. Renewed annual guidance signals improved visibility, yet the business faces near-term margin pressure and execution challenges as investments ramp.
Summary
- Industrial Expansion Outpaces Medical: Industrial revenue grew high single digits, offsetting medical’s slower trajectory.
- Growth Investments Weigh on Margins: R&D and channel development spend rose, compressing near-term operating leverage.
- Annual Guidance Returns: Management’s restored full-year outlook reflects improved demand visibility, but macro caution persists.
Business Overview
Varex Imaging designs and manufactures X-ray imaging components and systems, primarily serving the medical and industrial markets. The company generates revenue through the sale of imaging detectors, X-ray tubes, and security inspection systems, with its business split between the Medical segment (diagnostic imaging for healthcare) and Industrial segment (security, inspection, and non-destructive testing). EMEA, Americas, and Asia Pacific are its principal geographic markets, with EMEA historically representing a significant share of revenue.
Performance Analysis
Q2 performance showed a continuation of stable demand trends, with the Industrial segment delivering high single-digit growth year-over-year, while the Medical segment remained in the low single digits. EMEA revenue fell to 28% of total sales, its lowest in years, reflecting the wind-down of a large prior-year linear accelerator order and ongoing regional lumpiness. Management attributed this to the inherently cyclical and project-driven nature of industrial and security inspection sales, particularly in Europe.
Operating expenses were higher than expected, driven by accelerated R&D for medical products and channel development in industrial markets. This spending, while pressuring near-term margins, is intended to support future revenue growth and operational leverage. The company also incurred a non-cash charge related to mark-to-market adjustments on Micro-X shares, impacting reported EPS and EBITDA. Despite these headwinds, management emphasized that overall industrial growth remains robust on an annualized basis and expects continued high single-digit expansion in that segment.
- EMEA Drag: EMEA’s revenue decline is tied to last year’s outsized linear accelerator shipments, highlighting the region’s volatility.
- Operating Expense Surge: Growth initiative funding in R&D and channel buildout elevated OpEx, with the impact expected to moderate as revenue catches up.
- Non-Cash EPS Impact: A $1.8 million Micro-X mark-to-market charge reduced EPS by four cents, with no adjustment in reported metrics.
While medical growth remains muted, industrial and security inspection momentum, along with a diversified customer pipeline, provide positive offsets. Management’s decision to reinstate annual guidance underscores confidence in demand stability and improved forecasting discipline.
Executive Commentary
"So this quarter as well, the same type of buying patterns continued. There was nothing odd about the buying patterns in a way that would have concerned us...the effect of the environment is largely on costs and material availability, lead times, logistics, and not on the demand side of our products."
Colin, Chief Executive Officer
"We are fully funding a number of growth initiatives. And so sometimes in R&D and channel development, R&D for medical, and then the channel development activities and initiatives that we have for the industrial segment, sometimes they don't come in exactly as one plan. So there's a little bit of a movement there. But we are investing there. So they came in a little bit sooner."
Sonia, Chief Financial Officer
Strategic Positioning
1. Industrial Segment as Growth Engine
The industrial segment’s high single-digit growth is now the primary driver of Varex’s top-line momentum, compensating for medical’s slower pace. Security inspection, including new car scanner deployments, is gaining traction, with the sales pipeline described as “hefty and big.” This segment’s lumpiness is managed through diversified customer wins and geographic expansion, emphasizing resilience.
2. Medical Business: Photon Counting and Pipeline Diversification
Photon counting, an advanced CT imaging technology, is progressing with two CT OEMs and eight additional customers in other modalities. While major launches are still targeted for 2029, the pipeline’s expansion beyond CT into areas like breast imaging and digital radiography signals a longer-term growth lever for the medical segment.
3. Renewed Annual Guidance and Forecasting Discipline
After suspending annual guidance during COVID and supply chain turmoil, management has reinstated full-year visibility, citing stabilized demand, improved customer forecasting, and greater macro predictability in healthcare. This shift reflects confidence in the company’s operational footing and the reliability of its revenue base.
4. Pricing Power and Cost Pass-Through
Varex maintains selective pricing power, with the ability to pass through cost increases—especially for components like chips—when contracts are renewed. While annual contract cycles limit in-year adjustments, this mechanism provides some margin protection against input cost volatility.
5. Operational Leverage from Growth Investments
Current elevated OpEx is framed as a precursor to future margin expansion, as R&D and channel investments are expected to translate into revenue growth and improved operating leverage over time. Management reiterated that as these initiatives mature, headwinds will become tailwinds for profitability.
Key Considerations
Varex’s Q2 signals a business in transition, balancing near-term cost headwinds with strategic bets on industrial growth and next-generation medical technology. The return of annual guidance and stable demand provides reassurance, but execution on growth investments and regional diversification will be critical for margin recovery and sustained outperformance.
Key Considerations:
- Industrial Outperformance as Offset: Sustained high single-digit industrial growth is crucial for balancing medical segment softness.
- EMEA Volatility Persists: EMEA’s reduced share of revenue underscores the need for geographic diversification and less cyclicality.
- Photon Counting Commercialization: Broader modality adoption and pipeline expansion could unlock new medical revenue streams, but timelines remain extended.
- Margin Recovery Hinges on Execution: Realizing operating leverage from current R&D and channel investments is central to future profitability.
- Cost Pass-Through Limited by Contract Cycles: Annual renewals constrain the speed of margin recovery from input cost inflation.
Risks
Key risks include continued EMEA demand weakness, the inherent lumpiness of industrial and security inspection orders, and the lag between current growth investments and their revenue realization. Cost inflation and supply disruptions remain a threat, with pricing power only partially offsetting in-year pressure due to contract structures. Long development cycles for photon counting and dependence on OEM partners introduce execution risk to medical segment recovery.
Forward Outlook
For Q3 2026, Varex guided to:
- Revenue growth in line with the first half, expecting low single digits in medical and high single digits in industrial.
- Operating expense guidance provided, reflecting continued investment in growth initiatives.
For full-year 2026, management reinstated annual guidance:
- Overall revenue growth of approximately 3%, mirroring first-half trends and segment splits.
Management highlighted several factors that shape the outlook:
- Demand stability in healthcare and industrial segments despite macro and political uncertainty.
- Improved forecasting discipline and customer visibility, supporting more reliable annual planning.
Takeaways
Varex’s industrial segment is now the growth anchor, offsetting medical’s slow pace and regional volatility. Margin recovery will depend on the successful conversion of R&D and channel investments into revenue, while EMEA and medical remain watchpoints. Analysts should monitor the pace of photon counting commercialization and the sustainability of industrial momentum, as these will determine the trajectory into 2027 and beyond.
- Industrial Strength: High single-digit growth in industrial and security inspection is the key positive lever, balancing medical and EMEA softness.
- Investment Drag, Future Leverage: Elevated OpEx will need to translate into revenue for margin expansion to materialize in coming quarters.
- Guidance Credibility Restored: The return of annual guidance signals improved visibility, but execution risk remains around margin recovery and new product adoption.
Conclusion
Varex Imaging’s Q2 2026 results show a business stabilizing after prior volatility, with industrial growth and renewed guidance providing confidence. Margin pressure and regional weakness are near-term headwinds, but the company’s strategic investments and pipeline diversification position it for a more balanced recovery if execution holds.
Industry Read-Through
The quarter’s results reinforce the bifurcation between industrial and medical imaging demand, with project-driven lumpiness and geographic volatility a recurring theme for imaging component suppliers. Security inspection and non-destructive testing markets remain robust, indicating continued capital investment by governments and industry in infrastructure and safety. Photon counting’s slow but broadening adoption signals a multi-year technology upgrade cycle in medical imaging, with implications for OEMs and component suppliers. Pricing power limited by contract cycles is a cautionary signal for peers facing similar input cost inflation. Overall, investors should expect margin variability across the imaging sector as growth investments and supply chain normalization play out.